Viracta Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch VIRX and buy or sell other stocks, ETFs, and their options commission-free!

About VIRX

Viracta Therapeutics, Inc. a clinical-stage, biomarker-directed precision oncology company focused on new medicines for the treatment of virus-associated malignancies. It develops antiviral agent valganciclovir as an oral combination therapy which is in a Phase 2 clinical trial for EBV-positive lymphomas. 

CEO
Craig R. Jalbert
CEOCraig R. Jalbert
Employees
40
Employees40
Headquarters
Cardiff, California
HeadquartersCardiff, California
Founded
1998
Founded1998
Employees
40
Employees40

VIRX Key Statistics

Market cap
635.91K
Market cap635.91K
Price-Earnings ratio
-0.01
Price-Earnings ratio-0.01
Dividend yield
Dividend yield
Average volume
172.16K
Average volume172.16K
High today
$0.0166
High today$0.0166
Low today
$0.015
Low today$0.015
Open price
$0.015
Open price$0.015
Volume
19.20K
Volume19.20K
52 Week high
$0.58
52 Week high$0.58
52 Week low
$0.008
52 Week low$0.008

People also own

Based on the portfolios of people who own VIRX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.